Diasome

A Single-Blind, Placebo-Controlled, Dose-Ranging Trial of Oral Hepatic-Directed Vesicle Insulin Add-On to Oral Antidiabetic Treatment in Patients With Type 2 Diabetes Mellitus

Study

Latest Updates

News

Coming Soon: OPTI-2 Trial Results to be Presented at ADA on June 7th at 5pm EST

Diasome to Present Phase 2b Results from OPTI-2 Trial Evaluating HDV-Insulin Lispro in Type 1 Diabetes at ADA 86th Scientific Sessions

Diasome Pharmaceuticals Completes Enrollment in Phase 2b OPTI-2 Trial of HDV-Insulin Lispro for Type 1 Diabetes